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Abstract
The  accumulation  of  misfolded  proteins  in  neurons,  leading  to  the
formation  of  cytoplasmic  and  nuclear  aggregates,  is  a  common theme in
age-related neurodegenerative diseases, possibly due to disturbances of the
proteostasis and insufficient activity of cellular protein clearance pathways.
Lithium  is  a  well-known  autophagy  inducer  that  exerts  neuroprotective
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effects  in  different  conditions  and  has  been  proposed  as  a  promising
therapeutic  agent  for  several  neurodegenerative  diseases.  We  tested  the
efficacy of chronic lithium (10.4 mg/kg) treatment in a transgenic mouse
model of Machado-Joseph disease, an inherited neurodegenerative disease,
caused byan expansion of a polyglutamine tract within the protein ataxin-3.
A  battery  of  behavioral  tests  was  used  to  assess  disease  progression.  In
spite  of  activating  autophagy,  as  suggested  by  the  increased  levels  of
Beclin-1,  Atg7,  and  LC3-II,  and  a  reduction  in  the  p62  protein  levels,
lithium administration showed no overall  beneficial  effects  in  this  model
concerning  motor  performance,  showing  a  positive  impact  only  in  the
reductionof tremors at 24 weeks of age. Our results do not support lithium
chronic  treatment  as  a  promising  strategy  for  the  treatment  of  Machado-
Joseph disease (MJD).
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Introduction
Lithium, a monovalent cation and a FDA-approved drug with the ability to
cross the blood–brain barrier, has been used in the past 6 decades for the
treatment of bipolar disorder(BD) and also adjunctively with mood stabilizers
and antidepressants to enhance, prolong, and facilitate treatment response and
remission of mood disorders [ 1 , 2 ]. Although its therapeutic mechanisms
remain unclear, strong in vivo and in vitro evidence suggests that lithium has
neurotrophic/neuroprotective properties toward a wide range of insults, and
also in neurodegenerative diseases [ 3 , 4 ]. Lithium inhibits glycogen synthase
kinase-3 [ 5 , 6 ] and increases the protein levels of the brain-derived
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neurotrophic factor (BDNF) [ 7 , 8 ], leading to an enhanced cell survival.
Lithium also regulates calcium homeostasis and suppresses calcium-
dependent activation of pro-apoptotic signaling pathways [ 9 ], and it can
protect against endoplasmic reticulum (ER) stress [ 10 ], associated with
impaired synaptic plasticity and pathology in neurodegenerative conditions,
such as Alzheimer’s disease (AD) [ 11 ]. In order to be effective, lithium
requires long-term treatment, and its effects are not reverted immediately after
discontinuation. For this reason, it is thought that lithium acts at the gene
expression level. Indeed, lithium is able to upregulate the expression of
important molecules such as HSP70 [ 12 , 13 ], BCL-2 [ 9 , 14 , 15 ], BDNF [ 7 ,
8 , 16 ], HSF1 [ 13 ], and CREB [ 4 ], among others. Moreover, lithium
decreases inositol 1,4,5-trisphosphate by inhibiting phosphoinositol
phosphatases [ 17 , 18 ]; this was proposed as a novel mechanism to induce
autophagy [ 19 – 21 ]. Macroautophagy, commonly referred to as autophagy, is
an important process for the degradation of proteins and organelles and plays
a major role in cellular stress conditions [ 22 ]. It is also involved in neuronal
and astrocytic cell survival and function [ 23 ]. The process of autophagy
begins with the formation of double-membrane structures called
autophagosomes that fuse with lysosomes (autolysosomes) and lately degrade
their contents by lysosomal hydrolytic enzymes [ 24 , 25 ]. Autophagy recycles
cytoplasmic proteins in normal conditions and recycles nutrients when
necessary, for instance, under starvation. The accumulation of misfolded
proteins in cells is a common feature in aging and in several
neurodegenerative disorders [ 26 ], which makes autophagy a prominent target
for the treatment of such diseases; these include amyotrophic lateral sclerosis
(ALS), Parkinson disease (PD), AD, Huntington’s disease (HD), and
Machado-Joseph disease (MJD) [ 27 – 37 ]. Drugs that potentially modulate
autophagy are increasingly being used in clinical trials, and screens are being
performed for the discovery of new compounds that induce autophagy.
Autophagy is modulated by several signaling pathways and is directly
inhibited by the serine/threonine protein kinase mammalian target of
rapamycin (mTOR) [ 38 ]. Administration of rapamycin has been demonstrated
to be beneficial in different animal models of neurodegenerative disorders, by
enhancing autophagic function [ 24 , 29 , 36 , 39 , 40 ]. Autophagy can also be
regulated independently of mTOR, which can be achieved through lithium,
sodium valproate, and carbamazepine, compounds that lower myo-inositol-
1,4,5-triphosphate levels [ 20 , 41 ]. Lithium acts as an autophagy enhancer or
inhibitor, depending on the dosage. At higher doses, it inhibits GSK3β, which
suppresses autophagy [ 42 ]; in contrast, at lower doses, it inhibits IMPAse,
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inducing autophagy [ 20 ].
Chronic lithium treatment was tested in several models of neurodegenerative
diseases. Lithium was shown to have beneficial effects in patients and also in
an ALS mouse model [ 43 , 44 ]. The study in the mouse model demonstrated
neuroprotection by lithium, which delayed disease onset and duration and
increased lifespan. In the clinical trial, a randomized study of adults with ALS
showed that none of the patients treated with lithium died during the
15 months of the follow-up, and the disease progression was markedly
attenuated [ 44 ]. In a mouse model of HD, this treatment had variable effects;
lithium improved the motor performance and reduced depressive-like
behavior, but only when administered post-symptomatically [ 45 ];
furthermore, it had no effect on survival in this model [ 45 ]. Chronic treatment
with lithium also improved neurological function and hippocampal dendritic
arborization in a mouse model of SCA1 [ 46 ]. More recently, chronic lithium
treatment was shown to ameliorate the phenotype of a MJD Drosophila
model, partially by inhibiting GSK3β [ 47 ].
Taking into account the beneficial effects of lithium and its autophagy
induction properties, and considering that little is known about its possible
effects in MJD, we performed chronic lithium treatment in the CMVMJD135
mouse model [ 48 ]. Our results show limited beneficial effects of lithium
treatment;: Aalthough it subtly improved a few of the symptoms observed at
specific time points, it was not able to globally improve motor function in this
model. These findings do not support the idea that lithium is a good candidate
to treat MJD. This is of clinical relevance, since one may avoid the collateral
effects of trying lithium therapy in MJD patients.
Material and Methods
Transgenic Mice
We used the CMVMJD135 mice [ 48 ], which express an expanded version of
the human MJD1-1 cDNA (the 3 UIMs-containing variant of ATXN3) under
the regulation of the CMV promoter (ubiquitous expression) at
near-endogenous levels. All animals were maintained under standard
laboratory conditions: an artificial 12-h light/dark cycle (lights on from 8:00
to 20:00 h), with an ambient temperature of 21 ± 1 °C and a relative humidity
of 50–60 %; the mice were given a standard diet (4RF25 during the gestation
and postnatal periods, and 4RF21 after weaning, Mucedola SRL, Settimo
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Milanese, Italy) and water ad libitum. All procedures were conducted in
accordance with European regulations (European Union Directive 86/609
/EEC). Animal facilities and the people directly involved in animal
experiments (S.D.S, A.N.C) were certified by the Portuguese regulatory entity
—Direcção Geral de Veterinária. All of the protocols performed were
approved by the joint Animal Ethics Committee of the Life and Health
Sciences Research Institute, University of Minho. Health monitoring was
performed according to FELASA guidelines [ 49 ], confirming the Specified
Pathogen Free health status of sentinel animals maintained in the same animal
room. Humane endpoints for experiment were defined (20 % reduction of the
body weight, inability to reach food and water, presence of wounds in the
body, dehydration), but not needed as the study period was conceived to
include ages at which animals do not reach these endpoints.
Mouse Genotyping
The progenies produced by mating MJD transgenic with wild-type animals
were genotyped at weaning by PCR, as previously described [ 50 ].
Drug Treatment and Behavioral Tests
Male mice were used in the study since they show less variability than
females in behavioral tests, due to the more variable hormonal female status.
Transgenic and non-transgenic, drug- and vehicle-treated animals were housed
at weaning in groups of five animals per cage. The experiment started at
4 weeks and ended at 24 weeks of age. At 4 weeks of age, we screened the
overall status of the animals by the SHIRPA protocol before starting the
treatment with lithium chloride (LiCl, Merck, Massachusetts, USA). The
treatment started at the asymptomatic age of 5 weeks, 1 week before the
previously observed onset of symptoms [ 48 ].
We used a total of 40 animals, which were housed according to the drug
administered, since the experiment was carried out by a single experimenter,
which was only blind to the genetic status of the animals. The animals were
intraperitoneally injected three times per week, except in the week of
behavioral tests. Transgenic and non-transgenic littermates (n = 10 for each
genotype) were treated with 10.4 mg/kg of lithium chloride as previously
described [ 44 , 45 ]. Control littermate animals were given a vehicle injection
of buffer (0.15 M NaCl, 5 % Tween-20, and 5 % PEG 400) with the same
frequency. The animals were evaluated at 20 and 24 weeks of age in the Beam
Walk Balance test. The SHIRPA protocol was performed at all ages tested. For
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a detailed description of behavioral testing, see below.
Body Weight
All mice were weighed a week before the start of the drug treatment (4 weeks)
and then at 5, 6, 8, 9, 10, 12, 13, 14, 16, 17, 18, and 20 weeks of age.
Beam Walk Balance Test
The beam walk balance test assesses balance but is also sensitive to fine
motor coordination. This test measures the ability of the animal to stay upright
and to walk on an elevated beam without falling to the cushioned pads below,
or slipping to one side of the beam. The beams are 70 cm long and made of
smooth wood with a square (12 mm wide) or a round (11- and 17-mm
diameter) shape. The beam is placed at the height of 50 cm. The test has
different levels of difficulty obtained by varying the shape and width of the
beams. The animals were trained during 3 days in the square beam (12 mm).
In the fourth day, they were tested in the training beam and also in two round
beams (17 and 11 mm).
The animal is placed on one end of the beam and then allowed to walk along
the beam and reach the opposite end (which has a “safe” dark box). At the end
of the training days, the animals should be capable of performing the task in
less than 20 s. By day 4, animals were tested using two beams of different
width and shape (square and round). If the animal fell or turned around in the
beam, this was considered one failed trial. Each animal had the opportunity to
fail two times in each beam. The time the animal took to cross the beam was
counted, and time was discounted if the animal stopped in the beam.
SHIRPA Protocol
We established a protocol for phenotypic assessment based on the primary
screen of the SHIRPA protocol, which mimics the diagnostic process of
general neurological and psychiatric examination in humans [ 51 ]. Each
mouse was placed in a viewing jar (15-cm diameter) for 5 min and transferred
to a 15-labeled-squares arena (55 × 33 × 18 cm), and then a series of
anatomical and behavioral features were registered. The full details of the
SHIRPA protocol are available at the site http://empress.har.mrc.ac.uk
/browser/?sop_id=10_002_0 . In addition, we included the footprint pattern
test (see below) to assess gait [ 52 ] and the counting of rears over 5 min in the
viewing jar, as a measure of spontaneous vertical exploratory activity. The
protocol was adjusted in order to minimize animal handling and to generate
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uniformity in waiting times between the tests [ 53 ].
Footprint Pattern
The footprint test was used to evaluate the foot dragging of the animals. To
obtain footprints, the hindpaws and forepaws of the mice were coated with
black and red non-toxic paints, respectively. A clean rectangular paper sheet
was placed on the floor of the runway for each run. The animals were then
allowed to walk along a 100 cm long × 4.2 cm width × 10 cm height corridor
in the direction of an enclosed black box. Each animal was allowed to achieve
one valid trial per age. To evaluate the presence of foot dragging through age,
the footprinting pattern of CMVMJD135 and wild-type (wt) vehicle- and
lithium-treated (n = 10 per group) was analyzed at each time point considering
six consecutive steps (absent, no dragging; present, at least one step out of six
shows dragging).
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Assessment of Autophagy Activation
The animals that were chronically treated with LiCl for 19 weeksand were
killed 12 h after the last injection as previously described [ 48 ], and the brain
and muscle tissue were immediately frozen in dry ice. We also injected
wild-type animals with LiCl (10.4 mg/kg) three times in 1 week in alternate
days and performed the killing at different time points after the last injection:
6, 14, 16, 18, and 24 h for determination of acute effects. Another set of
animals was injected with the vehicle and killed at the same time points.
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Western Blot
Brain tissue was homogenized in cold 0.1 M Tris–HCl, pH 7.5, 0.1 M EDTA,
and a mixture of protease inhibitors (Complete, Roche, Swiss) and was
sonicated for 10 s. Protein concentration was determined using the Bradford
assay (Biorad, CA, USA). Samples were heated for 5 min at 100 °C and
microfuged for 10 s before loading. For each sample, 15 μg of total protein
was loaded into SDS-PAGE gels and then transferred to nitrocellulose
membranes (Amersham GE Healthcare, UK). After incubation with the
primary antibodies—rabbit anti-LC3 (1:1,000 Novus Biologicals, Littleton,
CO), rabbit anti-IMPA1 (1:1,000, Abcam, Cambridge, UK), rabbit anti-p62
(1:50, Abcam, Cambridge, UK), rabbit anti-Beclin-1 (1:1,000, Cell signaling,
Beverly, MA), rabbit anti-Atg7 (1:1000, Cell signaling, Beverly, MA), mouse
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anti-alpha-tubulin (1:100, DSHB, University of Iowa, Iowa), and mouse
anti-beta-actin (1:100, DSHB, University of Iowa, IA)—the secondary
antibodies were incubated at the following dilutions: anti-rabbit (1:10.000,
Santa Cruz, Dallas, TX, USA) and anti-mouse (1:10.000, Santa Cruz, Dallas,
TX, USA). Antibody affinity was detected by chemiluminescence (ECL kit,
Santa Cruz, Dallas, Texas, USA). Band quantification was performed using
the ImageJ software according to the manufacturer’s instructions, using alpha-
tubulin as the loading control.
Determination of Lithium Plasma Levels
The plasma lithium levels were measured applying the LITH assay using the
Dimension Vista® System (LITH Flex® reagent cartridge)–SIEMENS.
Statistical Analysis
Power analysis was used to determine the sample size [ 54 ]. Considering the
different variables under study, such as weight and time held in the hanging
wire, assuming a power of 0.8 and a significance level of 0.05, different
required sample sizes were obtained, depending on the specified smallest
detectable difference and the variability of the experimental groups. Based on
these calculations and bearing in mind that as the age of the animals increases,
also the mean differences increase and, possibly, the standard deviations, a
sample size ranging between five and ten animals was obtained, and therefore,
a sample of ten animals was chosen. For specific behavioral tests and time
points of analysis, see Supplementary Table S1 .
Continuous variables with normal distributions (K-S test p > 0.05) were
analyzed with the Student’s t test or two-way ANOVA (factors: genotype and
treatment). Behavioral data were subjected to the non-parametric
Mann–Whitney U test when variables were non-continuous or when a
continuous variable did not present a normal distribution (Kolmogorov-
Smirnov test p < 0.05). Categorical variables in the SHIRPA protocol were
analyzed by contingency tables (Fisher’s exact test). All statistical analyses
were performed using SPSS 22.0 (SPSS Inc., Chicago, IL). A critical value
for significance of p < 0.05 was used throughout the study.
Results
In the CMVMJD135 transgenic mouse model, mutant ataxin-3 expression is
close to the endogenous levels and the MJD-like symptoms are progressive in
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life, as observed in human patients [ 48 ]. In the current study, we confirmed
the onset of the neurological phenotype at 6 weeks of age, with loss of grip
strength, measured using the hanging wire test. At 20 weeks of age, the
animals showed a deficit in balance on the beam test. It was also possible to
observe tremors, foot dragging, and limb clasping. Furthermore, they
exhibited decreased locomotor and exploratory behavior late in life. This
model does not show premature death, allowing long-treatment periods—in
the present case, treatment was administered for 19 weeks, i.e., until the age
of 24 weeks, when animals display overt symptoms and a full-blown
neurological phenotype.
Autophagy Is not Altered in the Brain of CMVMJD135 Mice
At basal conditions, autophagic activity in 24-month-old CMVMJD135 mouse
brains did not differ from that of littermate controls (Fig. 1a ). Autophagy was
assessed by the measurement of protein levels of LC3-II (Fig. 1b ), an
autophagosome marker; of Beclin-1 (Fig. 1c ), a protein involved in the
nucleation step of autophagy; of Atg7 (Fig. 1d ) involved in the elongation
step of this process; of p62 (Fig. 1e ), an autophagy substrate; and of IMPA1
(Fig. 1f ), an enzyme responsible for the provision of inositol required for
synthesis of phosphatidylinositol and polyphosphoinositides. Our results
suggest that autophagy is neither impaired nor over-activated in this
transgenic mouse model of MJD.
Fig. 1
Autophagy basal levels in CMVMJD135 mice. a Representative Western blot
probed with LC3, Beclin-1, Atg7, p62, IMPA1, and tubulin antibodies. At least
three technical replicates were performed. b–f LC3-II, Beclin-1, Atg7, p62, and
IMPA1 protein levels were measured in brain lysates of CMVMJD135 mice (n 
= 5) and their littermate wild type (n = 5) at 24 months of age. LC3-II protein
levels were normalized both for LC3-I and α-tubulin; Beclin-1, Atg7, p62, and
IMPA1  were  normalized  for  α-tubulin.  *p < 0.05;  **p < 0.01;  ***p < 0.001
(Student’s t test)
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Lithium Chloride Induces Autophagy in the Mouse Brain
In order to verify if lithium chloride could induce autophagy at the dosage we
planned to administer (10.4 mg/kg), similar to that used by Fornai et al. [ 44
and Wood and Morton 45 ], we used a group of wild-type mice, injected them
with lithium chloride [ 45 ] three times per week, and measured the levels of
autophagy markers in the brain at different time points after the last injection
(6, 14, 16, 18, and 24 h post-injection). In these mice, in which the mean
plasma lithium concentration achieved was 0.3 ± 0.09 mmol/L, we were able
to observe an increase in the LC3-II/LC3-I ratio (Fig. 2a ) and a decrease in
IMPA1 (Fig. 2b) , an enzyme whose expression is directly inhibited by
lithium. According to the Guidelines for the use and interpretation of assays
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for monitoring autophagy in higher eukaryotes [ 55 ], LC3 is the only marker
for autophagosomes, but in mammalian cells, total LC3 protein levels may not
be altered after a cellular challenge; the most probable finding is the increase
in the conversion of LC3-I to LC3-II. LC3-I is abundant and stable in the
central nervous system, which is a parameter to take in consideration in this
type of measurements [ 55 ]. Importantly, the LC3-II/LC3-I ratio was increased
at the protein level in the brain of lithium-treated mice (Fig. 2a ). We also
found an increase in LC3-II/LC3-I ratio in muscle tissue (data not shown).
Consistently, Beclin-1, a protein involved in the nucleation step of the
autophagosome formation [ 56 ], was also increased in animals treated with
LiCl, supporting autophagy induction by this treatment (Fig. 2b ).
Furthermore, the levels of Atg7, a protein involved in the elongation step of
autophagosome formation, were also increased in the LiCl-treated animals
(Fig. 2c ). The decrease in p62 levels confirms that autophagy was occurring
without blockage (Fig. 2d ). The levels of IMPA1 were, as expected,
decreased (Fig. 2e ).
Fig. 2
Autophagy induction by acute lithium treatment. a  Anti-LC3 Western blot of
brain  lysates  of  wild-type  animals  injected  with  vehicle  (n = 4)  or  lithium
10.4 mg/kg (n = 4 for each time point); b Beclin-1 Western blot of brain lysates
of wild-type animals injected with vehicle (n = 4) or lithium 10.4 mg/kg (n = 4
for each time point); c Atg7 Western blot of brain lysates of wild-type animals
injected with vehicle (n = 4) or lithium 10.4 mg/kg (n = 4 for each time point); d
p62 Western blot of brain lysates of wild-type animals injected with vehicle (n 
= 4) or lithium 10.4 mg/kg (n = 4 for each time point); e anti-IMPA1 Western
blot analysis of brain lysates of wild-type animals injected with vehicle (n = 4)
or lithium 10.4 mg/kg (n = 4 for each time point); lithium-injected animals were
killed  at  different  time  points  as  shown in  the  graph;  vehicle  animals  were
killed  6  h  post-injection.  Alpha-tubulin  or  beta-actin  was  used  as  loading
control. *n p< 0.05; **n p< 0.01; ***n < 0.001 (Student’s t test)
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To complement these analyses, we measured the levels of autophagy markers
in the brain of the transgenic animals that were chronically treated with LiCl,
namely, the LC3-II/LC3-I ratio (Fig. 3a ), as well as protein levels of Beclin-1
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(Fig. 3b ), Atg7 (Fig. 3c ), p62 (Fig. 3d ), and IMPA1 (Fig. 3e ), and the results
were similar to those observed for the acute LiCl treatment, confirming that
autophagy remains induced in the chronically treated animals.
Fig. 3
Autophagy  induction  by  lithium  in  chronically  treated  transgenic  mice  at
24 weeks of age. a Anti-LC3 Western blot of brain lysates of transgenic animals
injected with vehicle (n = 4) or lithium 10.4 mg/kg (n = 4); b Beclin-1 Western
blot  of  brain  lysates  of  transgenic  animals  injected  with  vehicle  (n = 4)  or
lithium 10.4 mg/kg (n = 4); c Atg7 Western blot of brain lysates of transgenic
animals  injected  with  vehicle  (n = 4)  or  lithium  10.4  mg/kg  (n = 4);  d  p62
Western blot of brain lysates of transgenic animals injected with vehicle (n = 4)
or  lithium  10.4  mg/kg  (n = 4);  e  anti-IMPA1  Western  blot  analysis  of  brain
lysates of transgenic animals injected with vehicle (n = 4) or lithium 10.4 mg/kg
(n = 4); alpha-tubulin or beta-actin was used as loading control. *p < 0.05; **p 
< 0.01; ***p < 0.001 (Student’s t test)
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Intriguingly, and despite the efficacy of LiCl to induce autophagy, it did not
reduce the protein levels of mutant human ataxin-3 in the brain of LiCl-treated
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animals, which were comparable to those of vehicle-treated mice
(Supplementary Fig. S1 ).
Lithium Did not Improve Body Weight Loss in
CMVMJD135 Mice
We assessed the phenotype of the mice from 4 to 24 weeks of age (Fig. 4a ).
Animals were weighed at 4 (before the treatment) 5, 6, 8, 9, 10, 12, 13, 14, 16,
17, 18, and 20 weeks of age. One of the known collateral effects of lithium
treatment in human patients is weight gain [ 57 ], but we did not observe this
in our study. Chronic administration of LiCl had no effect on body weight in
wt animals, compared with wt animals treated with vehicle. At 12 weeks of
age, vehicle-treated CMVMJD135 mice started to lose weight compared to the
vehicle-treated wt animals (p = 0.024) as previously observed for this model
[ 48 ] (genotype: F  = 9.919; p = 0.003) and asit is known to occur in human
patients [ 58 ]; this body weight reduction was progressive in time, as shown in
Fig. 4b . No differences were found between vehicle- and lithium-treated
transgenic animals, i.e., lithium treatment did not improve this body weight
reduction.
Fig. 4
Effect of lithium treatment on body weight and strength of CMVMJD135 and
wt mice. a Schematic timeline for the behavioral analysis of lithium pre-clinical
trial. b The body weight in grams between 8 and 20 weeks of age was depicted
for wt and CMVMJD135 mice  treated with LiCl or  vehicle (n = 10 for  each
group).  c  Hanging  wire  test—all  transgenic  animals  display  a  worse
performance  in  holding  the  grid  with  age  (from  8  to  24  weeks  of  age).  A
maximum time of 2 min was given to each animal and the time that they took to
fall was registered (n = 10 for each group). Symbols represent mean ± SEM of
the  different  groups.  *p < 0.05;  **p < 0.01;  ***p < 0.001,  for  genotype factor
(two-way ANOVA)
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Lithium Treatment Had no Major Effect on Neurological
Deficits Present in CMVMJD135 Mice
We analyzed all the animals using the SHIRPA protocol [ 51 ] before the
treatment onset, at 4 weeks of age, and no differences were found between wt
and CMVMJD135 animals (data not shown), meaning that at this time point,
the transgenic animals did not show any symptoms of disease.
The first disease manifestation in the CMVMJD135 model is the loss of limb
strength given by the hanging wire test, which measures the time the mouse is
able to hold a grid with its hindlimbs and, mostly, forelimbs, before falling.
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Whereas wild-type animals—treated and vehicle groups—were almost always
able to complete the task (hanging in the grid for the maximum time, 2 min),
transgenic animals—both LiCl- and vehicle-treated groups—showed a
decreased latency to fall from the grid, worsening with age (genotype: F  = 
324.589; p = 1.6628 × 10 ) (Fig. 4c ).
At 16 weeks and subsequent ages, CMVMJD135 vehicle-treated animals
showed a decrease in exploratory behavior, given by the infrequent rearing
behavior, which progressed to almost no rearing at the age of 24 weeks (p < 
0.05). At 8 weeks of age, lithium-treated CMVMJD135 animals showed an
increase in exploratory behavior when compared with vehicle-treated
CMVMJD135 animals, given by the increase in number of rears in the
viewing jar (p = 0.026). This activity reached that of the vehicle-treated wt
animals at this age, but at later stages, the improvement was no longer seen
(Fig. 5a ). To further test exploratory locomotor activity, we counted the
number of squares travelled in the arena used in the SHIRPA protocol.
CMVMJD135 treated with vehicle showed a decrease in the number of
squares travelled in the arena at 20 and 24 weeks of age (p = 0.003 and p = 
0.002, respectively), which was not improved by chronic lithium treatment
(Fig. 5b ).
Fig. 5
Effect  of  lithium  treatment  upon  spontaneous  exploratory  activity  and  gait
quality.  a  Transgenic animals display decreased vertical locomotor activity at
16 weeks of age and subconsequent ages (n = 10 for each group); b Transgenic
animals travel less in the arena than wild-type animals at 20 and 24 weeks of
age; lithium treatment had no effect in this phenotype (n = 10 for each group). c
CMVMJD135  animals  have  abnormal  gait  at  20  and  24  weeks  of  age
(qualitative assessment) that is slightly reverted by LiCl at 24 weeks, although
not statistical significant (n = 10 for each group). d Quantitative analysis of the
foot  dragging:  Presence/absence  of  dragging  demonstrated  that  transgenic
animals drag their feet since 12 weeks of age, which was not ameliorated by
LiCl (n = 10 for each group). *p < 0.05; **p < 0.01; ***p < 0.001
1,39
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We also performed qualitative analysis of the gait in the open arena as
described by Rogers et al. [ 51 ]. We scored the animals with 0 when their gait
was normal, 1 when the animal had a fluid stepping but an abnormal walking,
and 2 when the animal had limited walking [ 51 ]. CMVMJD135 animals
started to have significantly worse gait scores at the age of 20 weeks (p = 
0.029), and at 24 weeks of age, 100 % of the animals had a visibly abnormal
gait (80 % of the animals were scored as 1, 10 % as 2, and 10 % as 0, p = 
0.000017) (Fig. 5c ). There was a trend toward improvement with lithium
treatment, but only at 24 weeks of age (80 % of the vehicle transgenic animals
were scored as having abnormal gait, in contrast with 67 % of the treated
transgenic animals, p = 0.054) (Fig. 5c ). Additionally, we performed a
semi-quantitative analysis of the foot dragging observed in the mice (Fig. 5d ).
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We found no significant differences in the footstep measurements between the
four groups at the ages tested, but it was possible to observe that
CMVMJD135 animals presented foot dragging at 12 weeks (p = 0.00002) and
that this symptom progressed in severity with age (p < 0.05). At 20 weeks of
age, all CMVMJD135 mice (100 %, p = 2 × 10 ) dragged their feet while
walking. Lithium was not able to rescue this phenotype.
When mice are picked up by the tail and suspended toward a surface, their
normal reflex is to extend all the four paws to anticipate the ground [ 59 ]. The
paw clasping phenotype, in which the animals contract the paws instead of
extending them, is observed in several mouse models with damage in the
cerebellum [ 60 , 61 ] or in the basal ganglia [ 62 , 63 ], and also in models of
AD [ 64 – 66 ]. In CMVMJD135 mice, this paw clasping phenotype was
detected at 24 weeks of age (p = 2 × 10 ), whereas wt animals never
presented this abnormal reflex (Fig. 6a ). Lithium treatment was not able to
rescue this aspect of the phenotype (Fig. 6a ).
Fig. 6
Effect of lithium treatment on limb clasping and tremors. a  Limb clasping is
observed in transgenic animals—treated and non-treated—at 24 weeks of age
(n = 10 for each group). b CMVMJD135 mice presented tremors since 16 weeks
of age; LiCl is able to decrease tremors in transgenic animals at 24 weeks of age
(n = 10 for each group). *p < 0.05; **p < 0.01; ***p < 0.001 (Fisher’s exact test)
−5
−6
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We also observed an increase in the percentage of transgenic animals
presenting tremors through age, starting at 16 weeks of age (p < 0.05), which
was, surprisingly, ameliorated with lithium treatment, this improvement being
significant only after a long period of administration (24 weeks of age, p = 
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0.02) (Fig. 6b ).
Lithium Fails to Rescue Balance and Fine Motor Deficits in
CMVMJD135 Mice
The balance beam test depends on the mouse’s ability to maintain balance
while traversing a narrow beam to reach a safe platform [ 67 ] and was used to
test the balance and fine motor coordination capabilities in CMVMJD135 and
wt animals, treated with LiCl or with the vehicle. At 20 weeks, CMVMJD135
animals were slower to traverse the round beams with 17 mm (genotype: F  
= 8.96; p = 0.005; genotype × treatment: F  = 5.260; p = 0.029) and 11 mm
of diameter (genotype: F  = 4.447; p = 0.042), but not significantly slower
in the 12-mm square beam, in which they had been trained; the difficulty in
performing this task was confirmed at 24 weeks of age, when transgenic
animals were slower in traversing the 12-mm square beam (genotype: F  = 
6.412; p = 0.016), the 17-mm round beam (F  = 5.315; p = 0.028), and the
11-mm round beam (genotype: F  = 5.041; p = 0.032) (Fig. 7 ). In the
11-mm round beam, transgenic mice showed a “crawling behavior” (when the
animal’s thorax and abdomen are in contact with the beam surface) and
dragged themselves across the beam. Lithium had no significant effects in the
performance in the beam of either wt or CMVMJD135 mice.
Fig. 7
Effect  of  lithium  treatment  on  balance  and  motor  coordination.  Each  bar
corresponds to the mean of two consecutive trials in each beam. The time to
traverse the beam was videotaped and then measured by the same experimenter.
Ten to 12 animals were used for each condition. *p < 0.05 for genotype factor
(two-way  ANOVA);  #p < 0.05  for  genotype × treatment  factor  (two-way
ANOVA)
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Discussion
One promising therapeutic strategy in diseases associated with misfolded
protein accumulation is the stimulation of cellular degradation pathways such
as macroautophagy. Here we have tested the effect of authophagy activation
by lithium in a mouse model of MJD, beginning at a pre-symptomatic age.
In this study, we confirmed the progressive neurologic phenotype of the
CMVMJD135 mouse model, through observation of the group of vehicle-
treated animals, which behaved as previously described [ 48 ]. Chronic lithium
treatment was, however, not able to rescue the neurological phenotype of
these mice. The disease-causing polyQ CAG repeat expansion in ataxin-3
might cause neurotoxicity both through a toxic gain of function and a loss of
the wild-type ataxin-3 normal function(s) [ 68 ]. Several molecular pathways
might be involved in MJD neuropathology, although the precise pathogenic
mechanism(s) is (are) not known [ 69 , 70 ]. Decreased autophagy is a cellular
process that might be included in these mechanisms [ 36 , 37 , 71 ]. An
autophagy impairment was recently proposed to occur in a mouse model of
MJD, as well as in the brain of MJD patients [ 37 ]. MJD pathogenesis has
been modeled through the expression of mutant ataxin-3 that causes aggregate
formation and toxicity, in cell models and in vivo [ 72 ], and autophagy has
been shown to be an effective cellular strategy for the clearance of these
aggregated proteins [ 73 , 74 ]. Menzies and colleagues demonstrated that
autophagy induction by rapamycin could improve rotarod performance in a
transgenic mouse model of MJD [ 36 ]; however, the MJD model used in this
study presented a very mild phenotype (not significantly different from
control mice from a statistical standpoint), and the authors proposed that this
hypothesis should be further confirmed in a model with more marked
phenotype. Also, in this study, the authors suggest that it would be of great
importance to test other compounds that can induce autophagy, such as
lithium. Here, we provide a complete behavioral analysis of the CMVMJD135
mouse model chronically treated with lithium chloride.
At basal conditions, it was not possible to observe significant differences in
protein levels of LC3-II, Beclin-1, Atg7, p62, and IMPA autophagy markers
when comparing CMVMJD135 with wild-type animals at 24 weeks of age
(when they have a well-established phenotype), suggesting that, in spite of the
neurodegenerative changes they show [ 48 ], the autophagy process is
functioning normally in the brain of these mice. This is in contrast with the
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findings in another transgenic mouse model of MJD, characterized by more
marked overexpression of ataxin-3 and a faster disease progression [ 75 ],
where it has been proposed that autophagy was over-activated but functional
only at early stages of the disease [ 37 ].
Given the previous results in other related neurodegenerative diseases and our
own results with 17-DMAG, which delayed disease progression the
CMVMJD135 mouse and induced autophagy[ 48 ], we reasoned that even if
autophagy is normal in these mice, it might be useful to boost the cells’
capacity to eliminate toxic ataxin-3 aggregates; hence, we proceeded with
chronic lithium treatment in the CMVMJD135 mice. In this study we selected
to use a dosage at the lower limit of the therapeutic range in order to avoid
cerebellar toxicity as much as possible. The efficacy of lithium as an
autophagy inducer in the brain was validated by the decrease in protein levels
of IMPA-1, induction of Beclin-1 and Atg7 protein levels, increased
LC3-II/LC3-I ratio, and decrease in p62 in treated CMVMJD135 mice. Our
reason for studying treatment of the CMVMJD135 mice before onset of the
symptoms was to have the strongest effect possible in the disease progression
and to see if we could prevent or delay the onset of the disease rather than
treat it once established, as mechanistically, we anticipated that it would be
harder to remove the larger nuclear inclusions than smaller cytoplasmic
aggregates. Considering the availability of a genetic test for MJD patients,
this early stage treatment design could be feasible for mutation carriers even
before they present clinical symptoms.
At the phenotypic level, LiCl treatment did not rescue the loss of body weight
observed in CMVMJD135 animals. Progressive weight loss is observed in
MJD patients [ 58 ], despite a normal appetite [ 76 ] and also in HD patients
[ 77 ]. It has been reported previously that treatment with LiCl
pre-symptomatically caused loss of body weight in a HD mouse model,
whereas a gain of body weight was observed when LiCl treatment was
performed in post-symptomatic animals [ 45 ]. We have not observed loss or
gain of body weight as result of the treatment here performed, which was
initiated 1 week before symptom onset. Intriguingly, at 8 weeks of age,
lithium-treated CMVMJD135 animals showed an increase in exploratory
behavior when compared with vehicle-treated CMVMJD135 animals, given
by the increase in number of rears in the viewing jar. This activity reached the
levels of vehicle-treated wt animals. We believe that this apparent (and
transient) amelioration might have been due to an improved reaction to the
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novelty of the test (i.e., an effect in mood) and not because lithium was having
benefic effects at the motor level, since this rescue of hypoactivity was not
manifested in other motor parameters and was not maintained through life.
The tremors observed in CMVMJD135 mice were ameliorated with lithium
treatment, this improvement being statistically significant only after a long
period of lithium administration. This is an intriguing finding because tremors
are often observed in BD patients taking lithium for long periods [ 78 ], being
a side effect of this drug. Additionally, tremors are not a major symptom in
MJD patients, but rather a rare manifestation [ 79 – 81 ] that can be treated with
levodopa or dopamine agonists [ 82 ]. Thus, the tremor rescue by lithium
treatment that we observed in CMVMJD135 mice at one of the time points of
analysis might not have a major impact in human patients.
Gait analysis was performed using qualitative analysis, given by the “the way
animals walk” in the arena—scored by the experimenter, as part of the
SHIRPA protocol [ 51 ]—and by the footprinting analysis [ 52 ], respectively.
In the qualitative gait analysis, vehicle-treated CMVMJD135 animals showed
visible deficits in gait at 20 and 24 weeks of age. In the last time point of
analysis (at 24 weeks), LiCl treatment appeared to improve the visible quality
of gait, but this effect was not statistically significant.
Regarding balance (balance beam test), abnormal reflexes (limb clasping), and
strength/fine motor coordination (hanging wire test), it was also not possible
to observe any amelioration of CMVMJD135 mice with lithium treatment. Of
notice, the number of animals used in the study allowed detection of a 50 %
effect size for all tests for at least one age, with the exception of the medium
square and small circle beams in the balance beam test and the exploratory
locomotor activity in the SHIRPA protocol (Supplementary Table S1 ).
Lithium was shown to have beneficial effects in motor performance (given by
rotarod analysis) in a transgenic mouse model of SCA1 [ 46 ] but had no effect
in motor performance in a HD mouse model when administered
pre-symptomatically [ 45 ]. The current study demonstrates that long-term
peri-symptomatically initiated lithium treatment had no major effects in a
mouse model of MJD. Depending on the concentration, lithium has
well-established collateral effects. At least, in mice, these side effects may be
the result of differences in the ability of some individual mice to clear LiCl
from the plasma. In humans, at a dose of 1.5 mEq/L the side effects are
considered mild, but anorexia [ 83 ], tremors [ 84 ], nausea, diarrhea, vertigo,
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confusion (American Psychiatric Association 2002), and cognitive impairment
can occur [ 85 ]. Of relevance to this pathology, irreversible cerebellar toxicity
due to lithium intoxication has long been recognized and can lead to ataxia,
nystagmus, and dysarthria [ 86 ]. The pathophysiology of lithium-related
ataxia appears to be related with loss of Purkinje cells in the cerebellum, with
sparing of the surrounding basket cells [ 87 ]. Clinicians are aware of these
risks and monitor lithium plasma levels of the patients’ closely. Side effects
need to be carefully analyzed since lithium can cause cerebellar toxicity even
at so-called therapeutic levels [ 88 ].
While completing the experiments for this article, a human clinical trial with
lithium carbonate was performed in MJD patients ( http://clinicaltrials.gov
/ct2/show/record/NCT01096082 ). This study demonstrated that lithium (at a
dose of 0.5–0.8 mEq/L) was safe and well tolerated by patients during the trial
period, but the disease progression was not improved after 48 weeks of
follow-up, given by the Neurological Examination Score for the Assessment
of Spinocerebellar Ataxia (NESSCA) and the Scale for the Assessment and
Rating of Ataxia (SARA) scales. However, the authors were able to show that
the patients treated with lithium had a slightly slower progression concerning
two quantitative ataxia assessment tools, the mean PATA rate and the Click
Test, as well as in the spinocerebellar ataxia functional index (SCAFI) and
composite cerebellar functional score (CCFS), when compared to patients
receiving placebo. Considering this minor improvement in a few ataxia
measures, the authors proposed that a larger number of patients should be
enrolled in a new clinical trial to clarify these results [ 89 ]. Although the
dosage used in our study is considerably lower than that used in the human
study, and our treatment was initiated 1 week before symptom onset, this
clinical trial is in accordance with the present study, where we could not find
improvement by chronic LiCl treatment in the coordination and ataxia
measurements, although some behavioral parameters, such as tremors and gait
quality, were slightly ameliorated. Furthermore, we used similar doses as
those administered in studies showing beneficial effects in mouse models of
ALS and HD [ 44 , 45 ] and confirmed that this dosage induced the expected
biological effects, namely concerning autophagy induction.
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Conclusion
In conclusion, the present study, demonstrates that chronic lithium treatment
is not able to rescue the CMVMJD135 mouse phenotype; our results do not
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support lithium treatment as a good approach for MJD, particularly as the
above mentioned side effects must be taken in consideration.
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Supplementary figure 1
Levels of human ataxin-3 in LiCl-treated animals. Anti-ataxin-3 western-blot
of  brain  lysates  of  transgenic  animals  injected  with  vehicle  (veh)  (n = 4)  or
lithium chloride (LiCl) 10.4 mg/Kg (n = 4) at 24 weeks of age. Actin was used
as loading control. *, **, *** represents the p < 0.05; 0.01 or 0.001, respectively
(test-t student). (GIF 14 kb)
High resolution image (TIFF 2617 kb)
Supplementary Table 1
Sample size calculations for each behavioral test assuming a power of 0.8 and a
significance level of 0.05. (GIF 22 kb)
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